Cargando…

Novel Synthetic DNA Immunogens Targeting Latent Expressed Antigens of Epstein–Barr Virus Elicit Potent Cellular Responses and Inhibit Tumor Growth

Infectious diseases are linked to 15%–20% of cancers worldwide. Among them, Epstein–Barr virus (EBV) is an oncogenic herpesvirus that chronically infects over 90% of the adult population, with over 200,000 cases of cancer and 150,000 cancer-related deaths attributed to it yearly. Acute EBV infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wojtak, Krzysztof, Perales-Puchalt, Alfredo, Weiner, David B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631996/ https://www.ncbi.nlm.nih.gov/pubmed/31137606 http://dx.doi.org/10.3390/vaccines7020044

Ejemplares similares

DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas
por: Zhu, Xizhou, et al.
Publicado: (2021)

Potential Cellular Functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr Virus
por: Smith, Danielle Westhoff, et al.
Publicado: (2013)

Epstein–Barr virus latent genes
por: Kang, Myung-Soo, et al.
Publicado: (2015)

Simplifying checkpoint inhibitor delivery through in vivo generation of synthetic DNA-encoded monoclonal antibodies (DMAbs)
por: Perales-Puchalt, Alfredo, et al.
Publicado: (2019)

Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens
por: Bordoloi, Devivasha, et al.
Publicado: (2021)

High Levels of Epstein-Barr Virus DNA in Latently Infected Gastric Adenocarcinoma
por: Ryan, Julie L., et al.
Publicado: (2008)

Human Cd4(+) T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1
por: Münz, Christian, et al.
Publicado: (2000)

Exposure to the Epstein–Barr Viral Antigen Latent Membrane Protein 1 Induces Myelin-Reactive Antibodies In Vivo
por: Lomakin, Yakov, et al.
Publicado: (2017)

Immunoinformatics prediction of potential B-cell and T-cell epitopes as effective vaccine candidates for eliciting immunogenic responses against Epstein–Barr virus
por: Olotu, Fisayo A., et al.
Publicado: (2021)

Epstein-Barr virus infection and variants of Epstein-Barr nuclear antigen-1 in synovial　tissues of rheumatoid arthritis
por: Masuoka, Shotaro, et al.
Publicado: (2018)

Are Selected Cytokines and Epstein–Barr Virus DNA Load Predictors of Hepatological Complications of Epstein–Barr Virus Infection in Children?
por: Moppert, Justyna, et al.
Publicado: (2023)

IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment
por: Perales-Puchalt, Alfredo, et al.
Publicado: (2018)

Vaccination against Epstein–Barr Latent Membrane Protein 1 Protects against an Epstein–Barr Virus-Associated B Cell Model of Lymphoma
por: Soo Hoo, Wesley I., et al.
Publicado: (2023)

ZEB1 Regulates the Latent-Lytic Switch in Infection by Epstein-Barr Virus
por: Yu, Xianming, et al.
Publicado: (2007)

Contribution of Epstein–Barr Virus Latent Proteins to the Pathogenesis of Classical Hodgkin Lymphoma
por: Vrzalikova, Katerina, et al.
Publicado: (2018)

Epigenetic specifications of host chromosome docking sites for latent Epstein-Barr virus
por: Kim, Kyoung-Dong, et al.
Publicado: (2020)

Epstein-Barr Virus Latent Membrane Protein-1 Expression in Nasopharyngeal Carcinoma
por: Salano, Valerie E., et al.
Publicado: (2021)

Epstein-Barr virus latent membrane protein 2A exacerbates experimental autoimmune encephalomyelitis and enhances antigen presentation function
por: Chang, Rhoda A., et al.
Publicado: (2012)

Recurrent Plasmodium falciparum Malaria Infections in Kenyan Children Diminish T-Cell Immunity to Epstein Barr Virus Lytic but Not Latent Antigens
por: Snider, Cynthia J., et al.
Publicado: (2012)

A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits
por: Escalante, Gabriela M., et al.
Publicado: (2020)

Epstein-barr virus induced cellular changes in nasal mucosa
por: Gelardi, Matteo, et al.
Publicado: (2006)

How Epstein-Barr Virus Induces the Reorganization of Cellular Chromatin
por: Rosemarie, Quincy, et al.
Publicado: (2023)

Synthetic DNA delivery by electroporation promotes robust in vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-Ig
por: Xu, Ziyang, et al.
Publicado: (2018)

Epstein-Barr Virus (EBV) Is Mostly Latent and Clonal in Angioimmunoblastic T Cell Lymphoma (AITL)
por: Bahri, Racha, et al.
Publicado: (2022)

Synthetic DNA Delivery of an Engineered Arginase Enzyme Can Modulate Specific Immunity In Vivo
por: Khoshnejad, Makan, et al.
Publicado: (2020)

Correction: Recurrent Plasmodium falciparum Malaria Infections in Kenyan Children Diminish T-Cell Immunity to Epstein Barr Virus Lytic but Not Latent Antigens
por: Snider, Cynthia J., et al.
Publicado: (2012)

The Nuclear Chaperone Nucleophosmin Escorts an Epstein-Barr Virus Nuclear Antigen to Establish Transcriptional Cascades for Latent Infection in Human B Cells
por: Liu, Cheng-Der, et al.
Publicado: (2012)

Establishment of Epstein–Barr Virus (EBV) Latent Gene-Expressing T-Cell Lines with an Expression Vector Harboring EBV Nuclear Antigen 1
por: Kanno, Hiroyuki, et al.
Publicado: (2023)

Variations of Epstein-Barr Virus Nuclear Antigen 1 in Epstein-Barr Virus-Associated Gastric Carcinomas from Guangzhou, Southern China
por: Chen, Jian-ning, et al.
Publicado: (2012)

Immunization With Fc-Based Recombinant Epstein–Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model
por: Zhao, Bingchun, et al.
Publicado: (2018)

A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation
por: Bhojnagarwala, Pratik S., et al.
Publicado: (2021)

The Epstein-Barr Virus
por: Payne, L. N.
Publicado: (1980)

Epstein-Barr Virus Associated Modulation of Wnt Pathway Is Not Dependent on Latent Membrane Protein-1
por: Webb, Natasha, et al.
Publicado: (2008)

Modulation of the tumor microenvironment by Epstein‐Barr virus latent membrane protein 1 in nasopharyngeal carcinoma
por: Yoshizaki, Tomokazu, et al.
Publicado: (2018)

Galectin-9 Facilitates Epstein-Barr Virus Latent Infection and Lymphomagenesis in Human B Cells
por: Xu, Jing-xiao, et al.
Publicado: (2023)

The Possible Effect of B-Cell Epitopes of Epstein–Barr Virus Early Antigen, Membrane Antigen, Latent Membrane Protein-1, and -2A on Systemic Lupus Erythematosus
por: Tu, Jianxin, et al.
Publicado: (2018)

Evaluation of plasma Epstein–Barr virus DNA as a biomarker for Epstein–Barr virus–associated Hodgkin lymphoma
por: Usha, Masuma Khatun, et al.
Publicado: (2021)

Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses
por: Kong, Xiang-Wei, et al.
Publicado: (2022)

The Epstein–Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization
por: Wang, Jiayu, et al.
Publicado: (2019)

Epstein-Barr Virus Nuclear Antigen 1 Increases the Expression of Viral Oncogenes and Cellular Genes in the HeLa Cell Line
por: Alipour, Amir Hossein, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ttrng1prlgll6sqtpnlehjgicj